Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by synovial joint inflammation leading to cartilage destruction and bone erosion. Early diagnosis and treatment is essential to minimise the risk of future joint damage and disability. Treatment options include conventional disease-modifying anti-rheumatic drugs (DMARDS) such as methotrexate, and biological therapies including tumour necrosis factor (TNF) inhibitors and interleukin-6 antagonists. However, some patients fail to respond to biologic therapies. An exciting new development is small molecule DMARDs targeting intracellular signalling pathways, which include Janus kinase (JAK) inhibitors. Other recent developments include a biologic DMARD that targets and suppresses the inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Rheumatoid Arthritis Content
Andrea Rubbert-Roth, EULAR 2021: The Phase 3 SELECT-CHOICE Study
It was a pleasure to meet with Prof. Andrea Rubbert-Roth (Kantonsspital St Gallen, St Gallen, Switzerland) to discuss the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. The abstract ‘Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying […]
Roy Fleischmann, EULAR 2021: The Open-label Extension of the SELECT-COMPARE Study
TouchIMMUNOLOGY were delighted to talk with Professor Roy Fleischmann (The University of Texas Southwestern Medical Center and The Metroplex Clinical Research Center, Dallas, TX, US) around the 3 year results from the open-label extension study of upadacitinib or adalimumab in patients with rheumatoid arthritis. ‘Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with […]
Peter Taylor, EULAR 2021: Coadministration of Filgotinib and Statins in Rheumatoid Arthritis
We were delighted to speak with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) around the safety of statin and filgotinib coadministration in patients with rheumatoid arthritis across the DARWIN and FINCH clinical trials. The abstract ‘CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS‘ (POS0660), was presented at the European […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 3)
After his presentation at ACR 2020, we spoke with Anthony Sebba (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 2)
We caught up with Anthony Sebba (Arthritis Associates, FL, USA) to talk about the results from his study analysing pain and other patient-reported outcomes in patients with rheumatoid arthritis. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 1)
We were delighted to speak to Anthony Sebba (Arthritis Associates, FL, USA) to discuss whether pain and inflammation are independent of each other in patients with rheumatoid arthritis. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in […]
Jeffrey Curtis, ACR 2020 – Results from the SEAM-RA Trial
It was an absolute pleasure to talk with Jeffrey Curtis (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss whether patients could maintain rheumatoid arthritis remission on monotherapy after discontinuing either methotrexate or etanercept (Clinical Trial Identifier: NCT02373813). The abstract entitled ‘Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid […]
David Walker, ACR 2020 – Filgotinib for the Treatment of Rheumatoid Arthritis
We talked to David Walker (Northumbria Healthcare NHS Trust, Newcastle upon Tyne, UK) about filgotinib for the relief of pain, fatigue and improved quality of life in patients with rheumatoid arthritis (Clinical Trial Identifier: NCT02873936). The abstract ‘Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients […]
Rene Westhovens, ACR 2020 – Results from the FINCH 3 Study (Part 2)
Following his presentation at ACR 2020, Rene Westhovens talked to us about the 52 week results of the FINCH 3 study. The phase 3 study evaluated the efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis (Clinical Trial Identifier: NCT02886728). The abstract ‘Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!